Measles morbillivirus

Measles morbillivirus
Name	Measles morbillivirus
Taxon	Measles morbillivirus
Genus	Morbillivirus
Family	Paramyxoviridae
Order	Mononegavirales

Measles morbillivirus. It is the sole causative agent of measles, a highly contagious and historically significant human disease. This negative-sense, single-stranded RNA virus is a member of the genus Morbillivirus within the family Paramyxoviridae. The virus is antigenically monotypic, meaning infection or vaccination confers lifelong immunity, a principle central to global eradication efforts led by the World Health Organization.

Virology

Measles morbillivirus is an enveloped virus with a non-segmented genome approximately 15,894 nucleotides in length. Its viral envelope is studded with two glycoprotein spikes: the hemagglutinin (H) protein, responsible for attachment to host cell receptors such as CD150 (SLAM), and the fusion (F) protein, which mediates viral entry. The replication cycle occurs in the cytoplasm of infected cells. The virus is closely related to other morbilliviruses affecting animals, including rinderpest virus (now eradicated), canine distemper virus, and peste des petits ruminants virus. Research into its structure and function has been advanced by institutions like the Centers for Disease Control and Prevention and the Robert Koch Institute.

Pathogenesis and transmission

Infection begins when the virus enters the respiratory tract via inhalation of infectious aerosols or droplets. Initial replication occurs in alveolar macrophages and dendritic cells in the lungs, followed by a primary viremia that spreads the virus to lymphoid tissues. A secondary, massive viremia then disseminates the virus to epithelial and endothelial surfaces throughout the body, including the skin, conjunctiva, and respiratory tract. Transmission is primarily through the air or via direct contact with infectious secretions; patients are contagious from four days before to four days after the appearance of the characteristic rash. The extreme contagiousness is reflected in its basic reproduction number (R₀), often cited between 12 and 18, one of the highest for human pathogens.

Clinical manifestations

After an incubation period of 10-12 days, the prodromal phase begins, featuring high fever, malaise, and the pathognomonic Koplik's spots on the buccal mucosa. This is followed by the classic maculopapular rash, which typically starts on the face and spreads downward. While often self-limiting, measles can lead to severe complications due to virus-induced immunosuppression. These include pneumonia (often due to secondary bacterial infection), acute encephalitis, and the rare but fatal late complication subacute sclerosing panencephalitis (SSPE). Outbreaks in vulnerable populations, such as those documented in Samoa or the Democratic Republic of the Congo, highlight its clinical severity.

Diagnosis and prevention

Clinical diagnosis is often sufficient during outbreaks, but laboratory confirmation is essential for surveillance. This includes detection of IgM antibodies via enzyme immunoassay or viral RNA through reverse transcription polymerase chain reaction (RT-PCR). The cornerstone of prevention is vaccination with the live-attenuated measles vaccine, typically administered in combination with vaccines for mumps and rubella as the MMR vaccine. Developed notably by pioneers like John F. Enders and Samuel L. Katz, vaccination has dramatically reduced global incidence. Post-exposure prophylaxis with immunoglobulin or vaccine can be used for susceptible contacts. Maintaining high population immunity through programs like the Expanded Programme on Immunization is critical.

Epidemiology

Prior to widespread vaccination, measles caused major epidemics worldwide every 2-3 years, resulting in an estimated 2.6 million deaths annually. While vaccination has reduced global mortality by over 70%, the virus remains endemic in many parts of Africa and Asia. Large outbreaks continue to occur in areas with low vaccination coverage due to conflict, misinformation, or weak health systems, as seen in recent years in Ukraine, Philippines, and Venezuela. The Americas region was declared free of endemic measles transmission in 2016, but importations from other regions pose an ongoing threat, underscoring the need for global herd immunity.

History

Descriptions of a measles-like illness date back to the 9th century by the Persian physician Rhazes. The virus was first isolated in tissue culture in 1954 by John F. Enders and Thomas C. Peebles, a breakthrough that enabled vaccine development. The subsequent licensure of vaccines in the United States in 1963 and their integration into global immunization programs transformed public health. A major historical milestone was the declaration of the global eradication of the related rinderpest virus in 2011, providing a template for measles elimination. Current efforts, coordinated by the World Health Organization and UNICEF through initiatives like the Measles & Rubella Initiative, aim for regional elimination and eventual worldwide eradication.

Category:Mononegavirales Category:Viral diseases